Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2024-04-15 Governance Information
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药独立董事工作制度（2024年4月修订）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, responsibilities, qualifications, nomination, election, and duties of independent directors within the company. The content is focused on governance practices, internal rules, and the structure related to independent directors. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document outlining internal governance practices and director duties. Therefore, it fits best under the category of Governance Information (CGR).
2024-04-15 Chinese
国邦医药关于召开2023年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of Guobang Pharmaceutical Group Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report, financial statements, or voting results, but rather the announcement and procedural information for the upcoming AGM. The document length is 3429 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-15 Chinese
国泰君安证券股份有限公司关于国邦医药集团股份有限公司募投项目结项并将节余募集资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guotai Junan Securities Co., Ltd. regarding the completion of fundraising investment projects by Guobang Pharmaceutical Group Co., Ltd. and the permanent supplementation of surplus raised funds into working capital. It includes detailed data on the raised funds, their management, usage, project completion status, surplus funds, and the approval process by the board and supervisory committee. The document references regulatory guidelines and approvals related to the use of raised funds and confirms compliance with relevant laws and regulations. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a regulatory compliance and verification report related to fundraising and use of proceeds, which fits best under Regulatory Filings (RNS) as it does not constitute a standalone audit report or a capital/financing update announcement but a regulatory compliance document verifying fundraising usage and project completion.
2024-04-15 Chinese
立信会计师事务所关于国邦医药2023年内部控制审计报告
Regulatory Filings
2024-04-15 Chinese
国邦医药2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business descriptions, industry position, shareholder information, and dividend distribution plans. The length of the document (9377 characters) and the presence of comprehensive financial and operational data indicate this is the actual annual report content, not just an announcement or summary notice. The document also references an audit report with an unqualified opinion, which is typical in annual reports. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-15 Chinese
立信会计师事务所关于国邦医药2023年度审计报告及财务报表
Regulatory Filings
2024-04-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.